SCHEMBL7835284

SCHEMBL7835284

O=C1c2ccccc2C(=O)c2ocnc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
MAPT P10636 2/20 0.47
RAB9A P51151 2/20 0.47
AHR P35869 1/20 0.47
PTPRC P08575 4/20 0.46
POLB P06746 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
APAF1 O14727 2/20 0.46
TDP2 O95551 2/20 0.46
S100A4 P26447 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CES2 O00748 1/20 0.46
TERT O14746 1/20 0.46
PLIN1 O60240 1/20 0.46
S1PR4 O95977 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22029242 0.86 PTPRC (0.53) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL32677553 0.86 PTPRC (0.53) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL8662686 0.69 ALDH1A1 (0.91) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL30898601 0.69 ALDH1A1 (0.91) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL1899280 0.68 PTPRC (0.88) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL29566445 0.68 PTPRC (0.88) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL9672807 0.68 PTPRC (0.69) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL7918737 0.67 MEN1 (0.52) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL2294786 0.67 CYP1A2 (0.39) KDM4EMAPK1
SCHEMBL31435352 0.67 MAPK14 (0.56) NPC1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3497083-B1 HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE COMMISSARIAT ENERGIE ATOMIQUE (FR) 2022-01-19 EP disclosed
EP-0876356-B1 USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF INNOTHERA SA LAB (FR) 2001-10-31 EP disclosed
US-6262095-B1 TREATMENT OF ILLNESS ASSOCIATED WITH AN ALTERATION IN VENOUS FUNCTION AND/OR INFLAMMATORY EDEMA LABORATOIRE INNOTHERA (FR) 2001-07-17 US disclosed